368 related articles for article (PubMed ID: 16945076)
1. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
[TBL] [Abstract][Full Text] [Related]
2. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
[TBL] [Abstract][Full Text] [Related]
5. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
6. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
7. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
[TBL] [Abstract][Full Text] [Related]
8. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
10. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
King MS; Brun SC; Kempf DJ
J Infect Dis; 2005 Jun; 191(12):2046-52. PubMed ID: 15897990
[TBL] [Abstract][Full Text] [Related]
11. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.
Flandre P; Delaugerre C; Ghosn J; Chaix ML; Horban A; Girard PM; Gladysz A; Cohen-Codar I; Van PN; Taburet AM; Rouzioux C; Delfraissy JF;
Antivir Ther; 2009; 14(1):93-7. PubMed ID: 19320241
[TBL] [Abstract][Full Text] [Related]
13. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
[TBL] [Abstract][Full Text] [Related]
14. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
[TBL] [Abstract][Full Text] [Related]
15. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
[TBL] [Abstract][Full Text] [Related]
16. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
[TBL] [Abstract][Full Text] [Related]
18. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
19. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
Katzenstein TL; Kirk O; Pedersen C; Lundgren JD; Nielsen H; Obel N; Nielsen C; Mathiesen LR; Gerstoft J
J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
[TBL] [Abstract][Full Text] [Related]
20. Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.
Guest JL; Ruffin C; Tschampa JM; DeSilva KE; Rimland D
Pharmacotherapy; 2004 Jun; 24(6):727-35. PubMed ID: 15222662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]